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Guillain-Barré syndrome is a major ordeal for every patient and often has a substantial mental, social, and financial impact as a result of intensive care treatment and neurorehabilitation due to the protracted trajectory of improvement.
THE EPONYM AND 100 YEARS OF CLINICAL ADVANCES George Guillain (ghee-lain 6 ) was a student of Pierre Marie, the recipient of the Charcot chair at the Salpêtrière (Figure 1, A) . Guillain was one of his most prolific pupils and would become his successor in 1925. In 1916, George Guillain, 1 Jean-Alexandre Barré, and André Strohl described acute and progressive limb weakness causing major difficulty in 2 soldiers they examined in an army hospital during the battle of the Somme (northern France, World War I). The key features were (1) the discovery of an unusual cerebrospinal fluid (CSF) finding of isolated albumin elevation without lymphocyte reaction (hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire)
1 not described previously in the setting of acute flaccid paralysis and (2) full recovery. The authors contemplated poisoning, neurosyphilis, anddconsidering the timesdtrench fever caused by Bartonella quintana leading to pain and stiffness due to myalgia.
Guillain and Barré ( Figure 1 , B) quickly named it notre syndrome (our syndrome), effectively expunging Strohl, but in the years following, clinicians often referred to it as Landry-Guillain-Barré syndrome. Landry had described similar but fatal manifestations of this affliction with progressive ascending weakness starting in all 4 limbs but also weakness involving the diaphragm, facial, laryngeal, and jaw muscles. 7 Before the weakness started, patients complained of fevers and bouts of severe pain. Landry's treatments included inhalation of chloroform, administration of opium, and use of electrical stimulation but also included pork chops and warm Bordeaux wine. 7 It is extremely likely that the disorder (assuming one disease) had been described earlier, and in our historical search, we found similar earlier clinical descriptions by François Chomel (1828), James Wardrop (1834), and, after Landry (1859) The fact is that Guillain and Barré published a large number of new observations and why the rather undistinguished 1916 publication would eventually lead to a major medical eponym remains unclear. Strohl was not included in the eponym for unknown reasons but his different specialty may have sidelined him particularly when the semiology of the disorder became a matter of debate.
Over the past 100 years, major advancements have occurred, and an alternative diagnostic termdacute inflammatory demyelinating polyradiculoneuropathydwas used more frequently. The devastating nature and global occurrence of GBS have led to worldwide contributions to the literature. Incremental understanding has come from hallmark publications: Haymaker and Kernohan's 1949 observation from 50 fatal cases identified early anterior root lymphocyte involvement that followed myelin edema, ie, an immunemediated polyradiculopathy 9 ; Wiederholdt, Mulder, and Lambert's 1964 study of 97 patients with electrophysiologic data emphasized a demyelinating polyradiculoneuropathy with lack of corticosteroid responsiveness 10 ; and Kurland and colleagues' studies in 1976 identified the association of the swine flu vaccination with an outbreak of GBS.
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For decades, GBS has been considered a demyelinating disorder with axonal injury in the more advanced cases. In Canada, Feasby et al 12 described the first purely axonal GBS cases in 1986, and subsequently in China in 1990, C jejuni infection was identified in such axonal-onset patients by a team of doctors from Johns Hopkins University (Ho, McKhann, Griffin, and Cornblath), the University of Pennsylvania (Asbury, Nachamkin), and Hebai Medical University (Li). [13] [14] [15] [16] In Japan in 1990, Yuki et al 17 identified ganglioside autoantibodies in axonal forms providing a specific mechanism of "molecular mimicry." Major breakthroughs in immunotherapy came with the North American plasma exchange treatment trial in 1985 18 and the Dutch intravenous immunoglobulin (IVIG) trial in 1992, 19 which confirmed efficacy, reduced duration of mechanical ventilation, and resulted in faster recovery. The landmark Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome clinical trial of IVIG and plasma exchange in 1997 20 found no benefit in combining treatment and led to the American Academy of Neurology practice parameter recommending either plasma exchange or IVIG. 21 
PATHOGENESIS
Multiple antecedent and potentially triggering events have been reported. 22 The association with infections is established in not only C jejuni but also cytomegalovirus, Epstein-Barr virus, influenza A, Mycoplasma pneumoniae, Haemophilus influenzae, hepatitis (A, B, and E). and Zika virus. [23] [24] [25] [26] The risk of GBS from influenza vaccine varies from 3 cases per million to as low as zero. [27] [28] [29] Surgery may predispose patients to GBS (more likely in patients with prior malignant or autoimmune disorders) but is exceedingly rare in our experience. 30 Guillain-Barré syndrome is often a postinfectious, immune-mediated nerve injury. Three phenotypes are likelydpurely demyelinating, purely axonal, and demyelinating with axonal involvement. Immunopathogenesis differs in each of these conceptual models, and outcome (possibly a response to treatment) is also different. The current working hypothesis of GBS immunopathogenesis is depicted in Figure 2 . Although both elements of the immune response (T cells and B cells) play a role, current understanding holds that GBS is antibody mediated. Not all antigangliose antibodies are neurotoxic, but antibodies binding to GM1 or GD1a gangliosides (at nodes of Ranvier) activate myelin-destroying complement. 31 The predominance of motor axonal involvement has led to the designation acute motor axonal neuropathy. Campylobacter jejuni infection is the main known instigator of this mechanism, and molecular mimicry between C jejuni lipooligosaccharide and GM1 and GD1a has been found. [32] [33] [34] [35] For patients presenting with the ataxic sensory variant, the most commonly identified ganglioside antigen FIGURE 2. Current understanding of Guillain-Barré syndrome pathogenesis and clinical variants. In demyelinating Guillain-Barré syndrome, unequivocal antigens have yet to be identified but are inferred by complement activation, myelin destruction, and cleanup by macrophages. In axonal and Miller Fisher variants, specific gangliosides (GM1, GD1a, GQ1b) are targeted by immunoglobulins and share antigenic epitopes with various bacterial and viral antigens. These antigenic targets are at nodal structures, at roots, and located at the end organs. In Miller Fisher syndrome, the GQ1b antigen also exists within the brain stem. In this variant, the macrophages clean up the axon debris and come in from the nodes. target is GQ1b. 36 Another motor-sensory axonal form of GBS (acute motor-sensory axonal neuropathy) can also be grouped under a more general term, axonal GBS. The target molecule in purely demyelinating disease is yet unknown. Despite this differentiation into subtypes, treatment is similar. Prognosis is worse with a more protracted course in axonal forms and more long-term disability.
CLINICAL PRESENTATION
The diagnosis of GBS is fairly typical, and the differential diagnosis is narrow. Symptoms and signs usually progress within 1 to 2 weeks. Severe back pain and distal limb paresthesias with a "tight band" feeling are common presenting signs, and the paresthesias gradually scatter over the limbs and move proximally. Although tingling is often the presenting symptom, sensory modalities remain normal to mildly impaired. Weakness begins in the more proximal muscles, causing difficulty with climbing stairs and getting out of a chair, and is most notable 1 or 2 days after the onset of paresthesias. Symmetric weak muscles are accompanied by depressed or absent deep tendon reflexes. Legs are more typically involved than arms, which creates the illusion of an ascending paralysis. Facial and oropharyngeal muscles are affected in 50% of the cases, and weakness of these muscle groups may be the initial manifestation. Patients may have development of halting, staccato speechdthe ability to speak only short sentences indicating shortness of breathdand have small tidal volume respiration with increased rate. Variants of GBS are more difficult to recognize and include Miller Fisher syndrome (oculomotor weakness, ataxia, and areflexia), [37] [38] [39] [40] pure paraparesis, [37] [38] [39] [40] [41] [42] pharyngeal-cervical-brachial weakness, bilateral facial palsy, bilateral lumbar polyradiculopathy, and acute severe midline back pain at onset. 41 Some of these variants blossom into a more characteristic clinical picture.
Neuromuscular respiratory failure is a most worrisome development, and it remains difficult for clinicians to appreciate its seriousness. Acute neuromuscular respiratory failure can be misinterpreted, and some seemingly stable patients could experience respiratory arrest. With hindsight in some instances, warning signs were present that could have prompted a better triagedpreferably to a monitored setting.
Abnormal Mechanics of Breathing
Normal quiet breathing is largely accomplished by contraction of the diaphragm. [43] [44] [45] [46] In general, the diaphragm is responsible for approximately two-thirds of the ventilatory effort to generate inspiration. It may be supplemented by accessory inspiratory muscles including the external intercostal, scalene, and sternocleidomastoid muscles. Expiration is mostly due to recoil of the thoracic cage, but abdominal wall muscles are also necessary to generate expiration and a forceful cough. Moving air into the lungs depends on respiratory load (ie, the sum of resistance of inspiratory flow, the resistance of the chest wall and lungs, and the positive pressure at peak expiration). 47 When inspiratory muscles contract, a negative force overcomes this respiratory load, resulting in inward movement of air. With weakness, the respiratory load can be only partly overcome, leading to less airflow and collapse of unfilled lung areas. Clinically, respiratory muscle weakness leads to low tidal volume ("shallow" breathing) and poor gas exchange, which in turn lead to tachypnea and later hypercapnia. In addition, these patients also have increased dead space ventilation next to their elevated respiratory drive. The rapid breathing results from signaling to the respiratory center from the abnormally weak respiratory muscle. Usually, this rapid breathing causes arterial PCO 2 to decrease, but when respiratory muscle strength is less than 25% of normal, PCO 2 will increase. Paradoxical breathing, also known as thoracoabdominal asynchrony, occurs with severe respiratory weakness. Clinically, it manifests as a rocking horseetype movement of the chest (outward) and abdomen (inward) and may occur with each breath (Figure 3 ).
Dysautonomia Patterns
Another manifestation of a developing neurocritical illness is dysautonomia, recognized by extreme blood pressure fluctuations and exaggerated drug responses, cardiac arrhythmias, hypersecretions, gastrointestinal tract dysfunction, and bladder dysfunction. [48] [49] [50] [51] [52] [53] [54] [55] Baroreflex abnormalitiesdaltered function due to vagal nerve demyelinationdmay cause these blood pressure fluctuations. 56 Moreover, because sympathetic nerves have less myelin, a sympathetic overdrive may occur. Dysfunction of afferent input from atrial stretch receptors could also influence blood pressure swings. 50 In severe GBS, a neurointensivist will have to differentiate veritable dysautonomia from early sepsis, pulmonary embolus, aspiration pneumonia, opioid overuse, and other guises including urethra obstruction. Another practical problem is that dysautonomia-treating drugs (eg, glycopyrrolate for increased secretions, neostigmine for ileus, b-blockers for tachycardia) [56] [57] [58] may cause cardiac arrhythmias or hypotension. Acute autonomic failure in GBS usually resolves in the plateau phase of the disorder and before improvement in motor function, but orthostatic hypotension may persist during the recovery phase.
MIMICKING DISORDERS
Very few disorders mimic GBS because their symptoms do not ascend, are not rapid, and are not postinfectious. The more likely candidates are presented in Table 1 . 59 Other disorders to consider are acute heavy metal intoxication, severe rhabdomyolysis (eg, rhabdomyolysis due to statin use), severe hypokalemia or hypophosphatemia, and intermittent porphyria. Guillain-Barré syndrome can be a first manifestation of chronic inflammatory demyelinating polyneuropathy, which typically worsens over 2 months. In these patients, recurrent attacks soon follow. 60 
LABORATORY TESTS
Cerebrospinal fluid analysis typically reveals high protein levels with a normal white blood cell count (the classic albuminocytologic dissociation). Although unusual, more than 10 white blood cells per high-power field may be seen but is more common in associated disorders such as Lyme disease, sarcoidosis, and AIDS. Because CSF can include a normal cell count and normal protein level in weak patients early in presentation, its usefulness is questionable. Lumbar puncture may be more appropriate in unclear clinical cases. Electrophysiologic studies are far more useful for diagnosis. Conduction block or decreased conduction velocities are indicators of demyelination. Specific tests for proximal nerve involvement seen early in the disease course include recording of F-waves and abnormalities like dispersion or dropout in F-wave signal. [61] [62] [63] [64] [65] Prolonged F-wave may be the only confirmatory finding if the patient is tested early. Needle electromyography will reveal reduced recruitment of motor unit potentials, but fibrillation potentials appear later. Other studies to consider are presented in Table 2 . Bedside pulmonary function tests are useful. Patients with diaphragmatic weakness have a decrease in the vital capacity when supine, but the decrease must be more than 25% from baseline to be called abnormal. Conversely, a normal supine vital capacity makes inspiratory muscle weakness highly unlikely. The maximal inspiratory pressure (MIP) has the advantage that recoil of the chest wall contributes to the value. A high MIP (>À80 cm H 2 O), particularly in combination with normal vital capacity, makes neuromuscular respiratory failure unlikely. Respiratory function tests are usually reliable but not in patients with severe facial weakness; this limitation can be overcome easily by using mask spirometry. Pulse oximetry is important in any patient with neuromuscular respiratory disease, but obviously it does not identify carbon dioxide retention. Rapid shallow breathing leads to chronic hypercapnia in patients with neuromuscular disease. Rapid shallow breathing markedly decreases total volume, shortens inspiratory time, and truncates vital capacity, resulting in hypercarbia. Overnight monitoring by pulse oximetry is essential because nocturnal hypoventilation indicates respiratory muscle weakness in the appropriate setting.
Arterial blood gas measurements can be informative. They may reveal hypoxemic, hypercapnic respiratory failure in a patient in obvious respiratory distress. However, in more subtle presentations, arterial blood gas measurements can be deceptive. Normal arterial blood gas levels may be seen in markedly fatigued patients, and one would expect a reduced PaCO 2 in a tachypneic patient. A normal arterial PCO 2 in a tachypneic patient, therefore, is a sign of impending fatigue because the patient cannot "blow off" carbon dioxide because of mechanical failure. Thus, hypercapnia is a late feature in acute neuromuscular failure. In other words, poor bellows lead to poor ventilation due to alveolar collapse resulting in hypoxemia. The blood gas measurement will indicate a "normal" PaCO 2 on repeated studies, only to increase when the system completely fails.
GENERAL MANAGEMENT
Many patients with GBS become bedbound, and this immobilization requires expert nursing care. Skin, eye, and mouth care is crucial to the comfort of quadriplegic patients.
Preventive Measures
Preventive measures are important. A bedside test for swallowing dysfunction is essential, and aspiration of thin liquid resulting in spontaneous cough during this test greatly increases the risk of aspiration. Enteral nutrition may be necessary in most patients. Intermittent pneumatic compression devices (along with subcutaneous heparin) are required to avoid deep venous thrombosis in the paralyzed legs, but these high-frequency devices cause discomfort in some patients. Infection surveillance is important, and a new infection should be carefully monitored for new-onset fever, increasing white blood cell count, and positive culture results. It is important to start physical therapy with passive range of motion in paralyzed limbs but without active strengthening, which may unnecessarily fatigue patients. Cramping pain is common and can be relieved by narcotics or nonsteroidal anti-inflammatory drugs. Carbamazepine or increasing doses of gabapentin or pregabalin may be helpful. Comfortable positioning of flaccid limbs using sheepskins may also be very therapeutic.
Immunotherapy
Plasma exchange removes antibodies and other possible inflammatory components such as complement and may improve T-cell suppressor function. The main modalities of initial treatment in GBS are 5 courses of plasma exchange (ie, 1.0-1.5 plasma volume exchange with 5% albumin or a crystalloid-colloid combination as replacement fluid). Large multicenter trials have established the effectiveness of plasma exchange in GBSdearlier clinical improvement, reduced need for mechanical ventilation, and faster recovery have been documented. Plasma exchange is most effective when started within 7 days of symptom onset. Two plasma exchanges are superior to none in mild GBS, and 4 exchanges are superior to 2 in moderately severe GBS. However, 6 exchanges are not superior to 4 in severe GBS requiring mechanical ventilation. 66 A recent Cochrane analysis confirms the efficacy of plasma exchange. 67 Alternatively, IVIG, 0.4 g/kg per day infusion at approximately 1 to 3 mL/min for 5 days, is used and also recommended for nonambulatory patients with GBS. Intravenous immunoglobulin is pooled IgG from thousands of donors, and its mechanism of action is not fully understood (presumably, neutralization of antibodies, Fc receptor blockade, or immunregulation on B or T cells). No randomized trials have compared IVIG with placebo for the treatment of GBS, but IVIG was found to be as effective as plasma exchange for the treatment of GBS and confirmed with a Cochrane systematic review of 5 trials. 68 Two large controlled trials have found IVIG and plasma exchange to have similar efficacy, but IVIG had fewer complications. 19, 20 The IVIG dose may be insufficient for some patients, which has led to a practice of repeating IVIG infusion. However, there is no evidence to support improved outcomes or faster pace of recovery with this repetition. Early relapse is very uncommon, but an additional course of plasma exchange or IVIG may result in return to baseline. 69 Combining IVIG with plasma exchange also has been tried without additional benefit. 20 Corticosteroids alone have no substantial benefit in GBS. Intravenous methylprednisolone in combination with IVIG may hasten recovery but does not considerably affect the long-term outcome or neuropathic pain from GBS. 70 Most physicians will start with IVIG first, but the costs are more than twice the cost of plasma exchange. 71 
ICU MANAGEMENT
The management of patients with GBS is difficult because of its unpredictable course, potential for rapid deterioration, and high chances for respiratory failure. Any patient with worsening weakness on initial evaluation or presentation requires admission and observation in an ICU (Figure 4) . However, only 1 in 3 patients will experience deterioration severe enough to mandate further or prolonged close monitoring and possibly endotracheal intubation. 22, 72 Respiratory failure and GBS can be assessed clinically, but pulmonary function tests using forced MIP and maximal expiratory pressure (MEP) and vital capacity can be quite useful. A vital capacity decrease to 20 mL/kg, MIP decrease to À30 cm H 2 O, and MEP decrease to 40 cm H 2 O (the "20-30-40 rule") are critical values warranting intubation. Others have found the following to be useful predictors of respiratory failure and the need for intubation: (1) the time between onset of weakness and hospital admission, (2) the presence of facial weakness or oropharyngeal dysfunction, and (3) the severity of limb weakness assessed by the Medical Research Council sum score. 73 As a general rule, imminent neuromuscular respiratory failure is typically recognized by restlessness, tachycardia with a heart rate of more than 100 beats/min, tachypneic respiratory rate of more than 20 breaths/min, use of sternocleidomastoid or scalene muscles, hesitant or constantly interrupting speech, asynchronous (and sometimes paradoxical) breathing, and the presence of forehead sweating ( Figure 4) . Notably, patients will continue to have a sensation of breathlessness even in the presence of normal blood gas levels. When PaCO 2 increases, patients will then experience "air hunger," 74, 75 which is a result of the increased respiratory drive and the hypercapnic stimulation of chemoreceptors. The sensation of hypoxemia, however, can be different, and patients will experience a sensation of "rapid breathing." Patients often have an unpleasant frightened feeling while struggling to breathe that indicates the need for intubation. Mechanical ventilation is often prolonged in GBS, and most patients will need tracheostomy. [76] [77] [78] Early tracheostomy is expected in elderly patients with preexisting pulmonary disease and in those with severe axonal involvement by electromyographic criteria. 72, 76, 78 If patients are intubated for oropharyngeal weakness and the disease continues to progress, tracheostomy should be performed also to avoid ventilator-associated pneumonia. 76 Postponing tracheostomy is an option in patients with dubious reasons for intubation or improving pulmonary function test results, but this postponement can be accomplished in only 1 in 5 patients at the most. 77 Generally, weaning from mechanical ventilation should be guided by improvement in diaphragm strength and normalization of values on serial pulmonary function tests. In GBS, diaphragmatic weakness may resolve before extremity weakness; thus, the timing of weaning should not be gauged solely by recovery of extremity muscle strength. Several conditions should be considered before even attempting to wean the patient from the ventilator. In addition, the patient should have no evidence of atelectasis, pleural effusion, or marked difficulty handling secretions. Secretion volume (less than hourly suctioning), whether the patient is comfortable with a T-piece trial, and normal chest radiographic findings offer some predictive value for successful extubation in patients with acute neuromuscular respiratory failure. Pulmonary function tests can predict weaning to some extent but are far from reliable. 79, 80 Markedly improved MEP that reflects expectoration of secretions, and thus abdominal musculature 
OUTCOME
Severe manifestations of GBS admitted to the neurosciences intensive care unit involves long-term respiratory care, management of dysautonomia (wide blood pressure swings and cardiac arrhythmias) and management of major systemic complications. Although supposedly benign when described initially, far more serious and critical appearences became recognized. 81 Several patients accounts of the experience have been published varying from titles such "My worst nightmare" (Byron Comp) to "Happily ever after" (Holly Gerlach) and often describe the alienation from body functions and complete dependency. Recovery often starts after the second or third week. Once the patient is mechanically ventilated, a prolonged ICU stay is anticipated, with a high number of patients needing tracheostomy tube placement even after early administration of plasma exchange or IVIG treatment. Still, many (w75%) mechanically ventilated patients have the ability to walk independently, even up to 2 years after disease onset. 82 In some studies, upper limb paralyses at peak disability has predicted decreased ability to ambulate. Nonetheless, patients may have clinically relevant improvement beyond 1 or 2 years; therefore, aggressive neurorehabilitation is warranted. 83 Full recovery is often seen; most patients regain ambulation, even in severe cases, but disability remains in up to 10%. It remains impossible, however, to predict who will stand up from a wheelchair and who will remain in one forever. Mortality in GBS has been estimated at 3% but doubles in patients who have been mechanically ventilated for months and may even approach 10% to 20% in patients with severe comorbidity.
Better ICU care and respiratory rehabilitation have greatly improved these percentages, but preexisting illness, in particular prior chronic obstructive pulmonary disease, and the fragility of very old age remain major disadvantages; patients may succumb from an otherwise trivial pneumonitis progressing to sepsis. After a bout of GBS, many patients are fatigued and need at least a year to recuperate and to return to their prior productivity level. 83 More valuable information will come from the International GBS Outcome Study which started in 2012 and aims to enroll 1000 patients.
PRECAUTIONS
Questions about vaccinations after GBS are very common but difficult to definitively answer because there might be some risk with any type of vaccination. No cases of GBS or recurrent GBS after any type of vaccination were found in a Kaiser Permanente study. 84 The benefit of influenza vaccination is great and in particular in elderly patients with pulmonary disease. The decision to proceed with vaccination is at the discretion of the physician in discussion of pro's and con's with the patient. Vaccination has been associated with GBS in other studies and has led to the Centers for Disease Control and Prevention issuing precautions against using influenza vaccine if a patient had GBS 6 weeks after a vaccination. 85 Still, the risk of relapse of GBS following vaccination is very small, and we have encountered a patient with a prior GBS with no relapse after 15 consecutive vaccinations. 86 FUTURE DIRECTIONS AND IMMEDIATE CHALLENGES Although GBS was initially described 100 years ago, its recent occurrence in association with the Zika virus emphasizes the importance of ongoing study of this disorder. 87 In those affected, the most common presentation was that of acute motor axonal neuropathy, with 19% having novel autoantibodies to the glycolipid GA1. The virus is spread by mosquitoborne infection and sexual transmission and will most likely spread to the Americas. Epidemiological research to identify and control outbreaks continues to be important. Additionally, many areas with a higher infection risk also have poor sanitation and limited access to modern neurointensive management. Lastly, we need to translate increased understanding of pathogenesis to meaningful treatment or prevention. Immunotherapeutic trials of blocking the complement cascade (ie, eculizumab, 88, 89 monoclonal antibodies binding to complement factor 5) are under way.
CONCLUSION
Guillain-Barré syndrome is a well-recognized, acute, disabling neurologic illness. Management is supportive with immunomodulating therapy but may involve prolonged intensive care and long-term neurorehabilitation. Without a full understanding of its pathophysiology, it will be difficult to find a treatment that dramatically hastens the slow recovery trajectory. Guillain-Barré syndrome can profoundly affect a patient's life and family because it may take years to resolve completely. Patients with GBS struggle and strive while undergoing neurointensive care and long-term rehabilitation, but the outcome is good for many.
Abbreviations and Acronyms: CSF = cerebrospinal fluid; GBS = Guillain-Barré syndrome; ICU = intensive care unit; IVIG = intravenous immunoglobulin; MEP = maximal expiratory pressure; MIP = maximal inspiratory pressure
